These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1063 related items for PubMed ID: 18635695

  • 1. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 2. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA.
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [Abstract] [Full Text] [Related]

  • 3. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A, Korotzer A, Gommoll C, Li D.
    Depress Anxiety; 2008 Oct; 25(10):854-61. PubMed ID: 18050245
    [Abstract] [Full Text] [Related]

  • 4. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, Modell JG.
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [Abstract] [Full Text] [Related]

  • 5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 7. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS, Aguiar LM, Kunz NR, Lei D.
    J Psychiatr Res; 2004 Jan; 38(3):249-57. PubMed ID: 15003430
    [Abstract] [Full Text] [Related]

  • 8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB, Thase ME, EPIC 014 Study Group.
    J Psychiatr Res; 2007 Nov; 41(3-4):351-9. PubMed ID: 16165158
    [Abstract] [Full Text] [Related]

  • 12. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [Abstract] [Full Text] [Related]

  • 13. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
    Bares M, Kopecek M, Novak T, Stopkova P, Sos P, Kozeny J, Brunovsky M, Höschl C.
    J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
    [Abstract] [Full Text] [Related]

  • 14. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.
    Depress Anxiety; 2007 Nov; 24(1):1-14. PubMed ID: 16894619
    [Abstract] [Full Text] [Related]

  • 15. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Gao K, Cui X, Nierenberg AA, OPERATION Study Team.
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [Abstract] [Full Text] [Related]

  • 16. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
    Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ.
    J Clin Psychopharmacol; 2006 Jun; 26(3):259-67. PubMed ID: 16702890
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    Thase ME.
    J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
    [Abstract] [Full Text] [Related]

  • 18. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.
    Luthringer R, Toussaint M, Schaltenbrand N, Bailey P, Danjou PH, Hackett D, Guichoux JY, Macher JP.
    Psychopharmacol Bull; 1996 Sep; 32(4):637-46. PubMed ID: 8993085
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.
    JAMA; 2000 Jun 21; 283(23):3082-8. PubMed ID: 10865302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.